liquid paraffin liquid
colorama pharmaceuticals ltd - liquid paraffin - oral liquid - 1ml/1ml
wecol 6.9 g powder for oral solution
stirling anglian pharmaceuticals ltd - macrogol 3350; sodium chloride; potassium chloride; sodium hydrogen carbonate - powder for oral solution - 6.9 gram(s) - osmotically acting laxatives; macrogol, combinations - osmotically acting laxatives - for the treatment of chronic constipation in adults, adolescents and the elderly. for resolving faecal impaction in adults, adolescents and the elderly. faecal impaction is defined as refractory constipation with faecal loading in the rectum and/or colon confirmed by physical or radiological examination of the abdomen and rectum.
wecol paediatric 6.9 g powder for oral solution
stirling anglian pharmaceuticals ltd - macrogol 3350; sodium chloride; potassium chloride; sodium hydrogen carbonate - powder for oral solution - 6.9 gram(s) - osmotically acting laxatives; macrogol, combinations - osmotically acting laxatives - for the treatment of chronic constipation in children aged 2 to 11 years. for the treatment of faecal impaction in children aged 5 years or above. faecal impaction is defined as refractory constipation with faecal loading in the rectum and/or colon.
briviact brivaracetam 10mg/ml oral solution bottle
ucb australia pty ltd t/a ucb pharma division of ucb australia - brivaracetam, quantity: 10 mg/ml - oral liquid, solution - excipient ingredients: sodium citrate dihydrate; purified water; methyl hydroxybenzoate; citric acid; glycerol; carmellose sodium; sorbitol solution (70 per cent) (crystallising); sucralose; flavour - briviact oral solution is indicated as add-on therapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 4 years of age with epilepsy
keppra levetiracetam 100 mg/ml oral solution bottle
ucb australia pty ltd t/a ucb pharma division of ucb australia - levetiracetam, quantity: 100 mg/ml - oral liquid, solution - excipient ingredients: acesulfame potassium; purified water; maltitol solution; methyl hydroxybenzoate; ammonium glycyrrhizinate; citric acid monohydrate; propyl hydroxybenzoate; sodium citrate dihydrate; glycerol; flavour - keppra (film coated tablets and oral solution) is indicated for - use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation, - monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. - add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme), and - add on therapy in the treatment of primary generalised tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalised epilepsy (ige). keppra concentrate solution for iv infusion after dilution is an alternative for patients when oral administration is temporarily not feasible.
dioralyte relief oral powder sachets blackcurrant
dendron brands ltd - sodium chloride; potassium chloride; sodium citrate; rice powder pre-cooked - powder for oral solution - 350mg ; 300mg ; 580mg ; 6gram
dioralyte relief oral powder sachets raspberry
dendron brands ltd - sodium chloride; potassium chloride; sodium citrate; rice powder pre-cooked - powder for oral solution - 350mg ; 300mg ; 580mg ; 6gram
picolax 10mg / 3.5g / 12 g powder for oral solution
ferring ireland ltd - sodium picosulphate; magnesium oxide, light ; citric acid, anhydrous - powder for oral solution - 10 mg/3.5 g/12 gram(s) - contact laxatives; sodium picosulfate, combinations
citrafleet powder for oral solution in sachet
casen recordati, s.l. autovia de logrono, km 13,300, 50180 utebo, zaragoza, spain - sodium picosulfate, magnesium oxide, light, citric acid, anhydrous - powder for oral solution - sodium picosulfate 10 mg magnesium oxide, light 3.5 g citric acid anhydrous 10.97 g - drugs for constipation
maxibar 98.45% w/w powder for oral suspension
bracco imaging spa - barium sulfate - powder for oral suspension - 98.45%w/w percent weight/weight - barium sulfate containing x-ray contrast media; barium sulfate with suspending agents